MatchMedi
한국어

Options mapped

Generalized myasthenia gravis (gMG): options by country

Sourced options by country plus visit-prep questions for Generalized myasthenia gravis (gMG). Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedRare diseaseLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

  • Which antibody result is documented: AChR, MuSK, LRP4, seronegative, or not yet tested?
  • Is the discussion about symptom control, steroid-sparing treatment, refractory disease, crisis prevention, pediatric use, or pregnancy planning?
  • For complement inhibitors, what meningococcal vaccination, prophylaxis, and REMS steps apply locally?
  • Is the local question about EU marketing authorization, England NHS access, or Germany/France reimbursement?

Trial-search terms to discuss

Generalized myasthenia gravis (gMG) clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

  • eculizumab (Soliris); ravulizumab-cwvz (Ultomiris); efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo); rozanolixizumab-noli (Rystiggo); zilucoplan (Zilbrysq); nipocalimab-aahu (Imaavy)[1]FDA-approvedanti-acetylcholine receptor (AChR) antibody positive; anti-muscle-specific tyrosine kinase (MuSK) antibody positive where stated; broader adult gMG label-expansion caveat for Vyvgart Hytrulo source; Targeted biologic/FcRn/complement therapies for antibody-defined gMG populations as stated in each U.S. label. · FDA approval does not establish payer coverage or suitability for a specific person. Complement inhibitors carry meningococcal vaccination/prophylaxis and REMS-related warnings. FcRn blockers include vaccination and infection/immune-globulin caveats. Antibody status, age, prior therapy response, crisis/exacerbation status, pregnancy, infection risk, and local payer rules require clinician review. Confidence/conflicts: High for U.S. label indications and antibody/age scopes; no conflict identified. Vyvgart IV current all-serotype expansion requires direct current IV label follow-up, so this finding records only the fetched Hytrulo label text.
  • eculizumab (Soliris); ravulizumab-cwvz (Ultomiris); efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo); rozanolixizumab-noli (Rystiggo); zilucoplan (Zilbrysq); nipocalimab-aahu (Imaavy)[1]FDA-approvedanti-acetylcholine receptor (AChR) antibody positive; anti-muscle-specific tyrosine kinase (MuSK) antibody positive where stated; broader adult gMG label-expansion caveat for Vyvgart Hytrulo source; Targeted biologic/FcRn/complement therapies for antibody-defined gMG populations as stated in each U.S. label. · FDA approval does not establish payer coverage or suitability for a specific person. Complement inhibitors carry meningococcal vaccination/prophylaxis and REMS-related warnings. FcRn blockers include vaccination and infection/immune-globulin caveats. Antibody status, age, prior therapy response, crisis/exacerbation status, pregnancy, infection risk, and local payer rules require clinician review. Confidence/conflicts: High for U.S. label indications and antibody/age scopes; no conflict identified. Vyvgart IV current all-serotype expansion requires direct current IV label follow-up, so this finding records only the fetched Hytrulo label text.

European Union

United Kingdom

  • pyridostigmine; prednisolone/steroids; immunosuppressants; intravenous immunoglobulin (IVIg); plasma exchange; thymectomy[3]Standard option (per NHS)not biomarker-specific in public NHS treatment framework; antibody testing and thymoma status remain separate clinical questions; Symptom relief, immune suppression, short-term rescue for severe symptoms, and surgical thymus management as described in NHS public guidance. · NHS public content is broad patient information and not a substitute for specialist neurology guidance, product labels, emergency management protocols, or national commissioning rules. It does not establish access to targeted biologics or define eligibility for thymectomy. Confidence/conflicts: Medium-high for broad UK public treatment categories; no conflict identified, but product-specific and commissioning-specific access requires separate sources.
  • pyridostigmine; prednisolone/steroids; immunosuppressants; intravenous immunoglobulin (IVIg); plasma exchange; thymectomy[3]Standard option (per NHS)not biomarker-specific in public NHS treatment framework; antibody testing and thymoma status remain separate clinical questions; Symptom relief, immune suppression, short-term rescue for severe symptoms, and surgical thymus management as described in NHS public guidance. · NHS public content is broad patient information and not a substitute for specialist neurology guidance, product labels, emergency management protocols, or national commissioning rules. It does not establish access to targeted biologics or define eligibility for thymectomy. Confidence/conflicts: Medium-high for broad UK public treatment categories; no conflict identified, but product-specific and commissioning-specific access requires separate sources.
  • pyridostigmine; prednisolone/steroids; immunosuppressants; intravenous immunoglobulin (IVIg); plasma exchange; thymectomy[3]Standard option (per NHS)not biomarker-specific in public NHS treatment framework; antibody testing and thymoma status remain separate clinical questions; Symptom relief, immune suppression, short-term rescue for severe symptoms, and surgical thymus management as described in NHS public guidance. · NHS public content is broad patient information and not a substitute for specialist neurology guidance, product labels, emergency management protocols, or national commissioning rules. It does not establish access to targeted biologics or define eligibility for thymectomy. Confidence/conflicts: Medium-high for broad UK public treatment categories; no conflict identified, but product-specific and commissioning-specific access requires separate sources.

Australia

  • efgartigimod alfa (Vyvgart)[4]TGA-registered (Australia)anti-acetylcholine receptor (AChR) antibody positive; add-on to standard therapy in adult anti-AChR-antibody-positive gMG, as stated by the TGA assessment. · The Australian indication is add-on to standard therapy and adult/AChR-positive. This entry records regulator status, not PBS subsidy, crisis treatment, or individual eligibility. Confidence/conflicts: High for Australian Vyvgart regulatory status; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • efgartigimod alfa (Vyvgart)[4]TGA-registered (Australia)anti-acetylcholine receptor (AChR) antibody positive; add-on to standard therapy in adult anti-AChR-antibody-positive gMG, as stated by the TGA assessment. · The Australian indication is add-on to standard therapy and adult/AChR-positive. This entry records regulator status, not PBS subsidy, crisis treatment, or individual eligibility. Confidence/conflicts: High for Australian Vyvgart regulatory status; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • ravulizumab (Ultomiris)[5]TGA-registered (Australia)anti-acetylcholine receptor (AChR) antibody positive; add-on to standard therapy in adult anti-AChR-antibody-positive gMG, as stated by TGA. · The fetched TGA page verifies the indication but does not provide full product-information details, payer status, or crisis-treatment criteria. Complement-inhibitor infection/vaccination precautions should be checked in the current product information. Confidence/conflicts: Medium-high for Australian registration status; full current PI/PBS details remain source-pending. Availability/reimbursement outside the approving regulator not established.
  • ravulizumab (Ultomiris)[5]TGA-registered (Australia)anti-acetylcholine receptor (AChR) antibody positive; add-on to standard therapy in adult anti-AChR-antibody-positive gMG, as stated by TGA. · The fetched TGA page verifies the indication but does not provide full product-information details, payer status, or crisis-treatment criteria. Complement-inhibitor infection/vaccination precautions should be checked in the current product information. Confidence/conflicts: Medium-high for Australian registration status; full current PI/PBS details remain source-pending. Availability/reimbursement outside the approving regulator not established.
  • rozanolixizumab (Rystiggo)[6]TGA-registered (Australia)anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive; add-on to standard therapy for adult anti-AChR-positive or anti-MuSK-positive gMG in Australia. · TGA product information notes additional monitoring in Australia and says the AusPAR PI may have been superseded by the current PI on the TGA product-information database. PBS status was not verified in this pass. Confidence/conflicts: High for Australian registration and indication; reimbursement remains source-pending. No conflict identified.
  • zilucoplan (Zilbrysq)[7]TGA-registered (Australia)anti-acetylcholine receptor (AChR) antibody positive; add-on to standard therapy for adult anti-AChR-antibody-positive gMG in Australia. · TGA describes the RAISE study population as adults with anti-AChR-positive gMG, MGFA class II-IV, MG-ADL score at least 6, and QMG score at least 12. Public subsidy/PBS status was not established from this regulator source. Confidence/conflicts: High for Australian regulatory approval and indication; PBS/reimbursement remains source-pending. No conflict identified.

Thailand

  • ravulizumab (Ultomiris)[8]Approvedanti-acetylcholine receptor (AChR) antibody-positive; add-on to standard therapy in adult anti-AChR-antibody-positive gMG; chronic-administration setting per source. · Ravulizumab must be administered by a healthcare professional under supervision of a physician experienced in neuromuscular disorders. The label states treatment in adult gMG has only been studied in chronic administration, ravulizumab has not been studied in gMG patients with MGFA Class V, and pediatric gMG safety and efficacy have not been established. This entry does not establish Thai reimbursement, center availability, or use in anti-AChR-negative gMG. Confidence/conflicts: High for Thai NDI Ultomiris anti-AChR-positive adult gMG label content; no conflict identified. Reimbursement/access and other gMG biologics remain unresolved.

Canada

  • efgartigimod alfa (Vyvgart)[9]Health Canada approvedanti-acetylcholine receptor (AChR) antibody positive; adult anti-AChR-antibody-positive gMG in Canada. · The product monograph records IV efgartigimod alfa. Separate subcutaneous Canadian product information exists but was not the primary source for this finding. This entry does not establish provincial reimbursement. Confidence/conflicts: High for Canadian IV Vyvgart label status; no conflict identified.
  • efgartigimod alfa (Vyvgart)[9]Health Canada approvedanti-acetylcholine receptor (AChR) antibody positive; adult anti-AChR-antibody-positive gMG in Canada. · The product monograph records IV efgartigimod alfa. Separate subcutaneous Canadian product information exists but was not the primary source for this finding. This entry does not establish provincial reimbursement. Confidence/conflicts: High for Canadian IV Vyvgart label status; no conflict identified.
  • ravulizumab (Ultomiris)[10]Health Canada approvedanti-acetylcholine receptor (AChR) antibody positive; adult anti-AChR-antibody-positive gMG in Canada. · The product monograph includes a serious warning for meningococcal infections and states Ultomiris is available in Canada under a controlled distribution/patient-support program. It does not establish provincial reimbursement or crisis use. Confidence/conflicts: High for Canadian ravulizumab gMG label status; no conflict identified.
  • ravulizumab (Ultomiris)[10]Health Canada approvedanti-acetylcholine receptor (AChR) antibody positive; adult anti-AChR-antibody-positive gMG in Canada. · The product monograph includes a serious warning for meningococcal infections and states Ultomiris is available in Canada under a controlled distribution/patient-support program. It does not establish provincial reimbursement or crisis use. Confidence/conflicts: High for Canadian ravulizumab gMG label status; no conflict identified.
  • ravulizumab (Ultomiris), with reimbursement-context comparators including efgartigimod alfa, IVIg, rituximab, eculizumab, plasma exchange, acetylcholinesterase inhibitors, corticosteroids, and nonsteroidal immunosuppressants[11]Approvedanti-acetylcholine receptor (AChR) antibody positive; Canadian reimbursement-with-conditions context for adults with anti-AChR-positive gMG whose symptoms persist despite standard therapy. · CADTH is a reimbursement body, not a prescribing label. The review notes uncertainty in relative efficacy compared with relevant comparators and states price reduction is required for cost-effectiveness. Confidence/conflicts: High for CADTH reimbursement recommendation context; provincial implementation and individual access remain source-pending.
  • ravulizumab (Ultomiris), with reimbursement-context comparators including efgartigimod alfa, IVIg, rituximab, eculizumab, plasma exchange, acetylcholinesterase inhibitors, corticosteroids, and nonsteroidal immunosuppressants[11]Approvedanti-acetylcholine receptor (AChR) antibody positive; Canadian reimbursement-with-conditions context for adults with anti-AChR-positive gMG whose symptoms persist despite standard therapy. · CADTH is a reimbursement body, not a prescribing label. The review notes uncertainty in relative efficacy compared with relevant comparators and states price reduction is required for cost-effectiveness. Confidence/conflicts: High for CADTH reimbursement recommendation context; provincial implementation and individual access remain source-pending.
  • rozanolixizumab (Rystiggo)[12]Health Canada approvedanti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive; adult anti-AChR-antibody-positive or anti-MuSK-antibody-positive gMG in Canada. · Health Canada has not authorized a pediatric indication because no efficacy and safety data in patients under 18 were available. Geriatric data are limited in the gMG placebo-controlled study. Confidence/conflicts: High for Canadian approval and adult anti-AChR/anti-MuSK indication; public reimbursement implementation remains separate. No conflict identified.
  • zilucoplan (Zilbrysq)[13]Health Canada approvedanti-acetylcholine receptor (AChR) antibody positive; adult anti-AChR-antibody-positive gMG in Canada, with standard therapy continued in the pivotal-trial context. · Health Canada states pediatric safety and efficacy below age 18 have not been established and Zilbrysq is not indicated for pediatric patients. The monograph states Zilbrysq must not be initiated in patients not vaccinated against Neisseria meningitidis or with unresolved Neisseria meningitidis infection. Confidence/conflicts: High for Canadian approval and indication; public-plan implementation remains a separate payer question. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • zilucoplan (Zilbrysq); rozanolixizumab (Rystiggo)[14]Approvedanti-AChR positive for zilucoplan; anti-AChR or anti-MuSK positive for rozanolixizumab; Canadian public reimbursement-with-conditions context for targeted gMG therapies, not a regulator indication expansion. · CDA-AMC recommendations are not the same as provincial listing. Coverage depends on public-plan implementation, clinical criteria, price conditions, and local formulary decisions. Confidence/conflicts: Medium-high for CDA-AMC/pCPA access context; provincial implementation not verified here. No conflict identified between regulator labels and payer recommendations, but reimbursement criteria are narrower operationally than label language.
  • zilucoplan (Zilbrysq); rozanolixizumab (Rystiggo)[14]Approvedanti-AChR positive for zilucoplan; anti-AChR or anti-MuSK positive for rozanolixizumab; Canadian public reimbursement-with-conditions context for targeted gMG therapies, not a regulator indication expansion. · CDA-AMC recommendations are not the same as provincial listing. Coverage depends on public-plan implementation, clinical criteria, price conditions, and local formulary decisions. Confidence/conflicts: Medium-high for CDA-AMC/pCPA access context; provincial implementation not verified here. No conflict identified between regulator labels and payer recommendations, but reimbursement criteria are narrower operationally than label language.

Sources

  1. U.S. Food and Drug Administration — official drug label · official drug label
  2. European Medicines Agency (EMA) — regulator product information · regulator product information
  3. NHS — national public health treatment information · national public health treatment information
  4. Therapeutic Goods Administration (TGA) — Australian Public Assessment Report · Australian Public Assessment Report
  5. Therapeutic Goods Administration (TGA) — prescription medicine new-indication registration page · prescription medicine new-indication registration page
  6. Therapeutic Goods Administration (TGA) — prescription medicine registration page · prescription medicine registration page
  7. Therapeutic Goods Administration (TGA) — Australian Prescription Medicine Decision Summary · Australian Prescription Medicine Decision Summary
  8. Thai National Drug Information / Thai FDA-MOPH — SmPC PDF / regulator drug-information repository · SmPC PDF / regulator drug-information repository
  9. Health Canada / argenx product monograph — official product monograph · official product monograph
  10. Alexion / Health Canada product monograph format — official product monograph · official product monograph
  11. CADTH via NCBI Bookshelf — reimbursement recommendation / health technology review · reimbursement recommendation / health technology review
  12. Health Canada Drug and Health Products Portal — Summary Basis of Decision · Summary Basis of Decision
  13. Health Canada Drug and Health Products Portal — Summary Basis of Decision · Summary Basis of Decision
  14. Canada's Drug Agency / CDA-AMC — reimbursement recommendation · reimbursement recommendation

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • efgartigimod alfa (Vyvgart); rozanolixizumab (Rystiggo); zilucoplan (Zilbrysq)Clinical trialClinical trialReported in a clinical trialJapan · Japan efgartigimod source describes broad gMG after insufficient steroid or non-steroid immunosuppressive response; China efgartigimod source specifies adult anti-AChR antibody-positive gMG; Japan UCB source specifies adult gMG after inadequate response to steroids or other immunosuppressants and notes antibody context for Zilbrysq/Rystiggo supporting data; Japan adult gMG after insufficient response to steroids/ISTs for Vyvgart, Rystiggo, and Zilbrysq per manufacturer approval announcements; China adult anti-AChR-positive gMG add-on therapy for Vyvgart; South Korea registry/trial participation for adult and pediatric gMG investigational or approved-in-other-jurisdiction agents. · Japan and China approval claims here are manufacturer-sourced rather than direct PMDA/NMPA labels. South Korea has trial geography verified, but MFDS label/reimbursement remains source-pending. ClinicalTrials.gov records do not establish routine availability. Confidence/conflicts: Medium for Japan/China routine availability because direct regulator labels were not fetched; high for manufacturer-stated approvals and trial geography/status. No direct conflict identified. argenx — manufacturer regulatory approval announcement
  • efgartigimod alfa (Vyvgart); rozanolixizumab (Rystiggo); zilucoplan (Zilbrysq)Clinical trialClinical trialReported in a clinical trialJapan · Japan efgartigimod source describes broad gMG after insufficient steroid or non-steroid immunosuppressive response; China efgartigimod source specifies adult anti-AChR antibody-positive gMG; Japan UCB source specifies adult gMG after inadequate response to steroids or other immunosuppressants and notes antibody context for Zilbrysq/Rystiggo supporting data; Japan adult gMG after insufficient response to steroids/ISTs for Vyvgart, Rystiggo, and Zilbrysq per manufacturer approval announcements; China adult anti-AChR-positive gMG add-on therapy for Vyvgart; South Korea registry/trial participation for adult and pediatric gMG investigational or approved-in-other-jurisdiction agents. · Japan and China approval claims here are manufacturer-sourced rather than direct PMDA/NMPA labels. South Korea has trial geography verified, but MFDS label/reimbursement remains source-pending. ClinicalTrials.gov records do not establish routine availability. Confidence/conflicts: Medium for Japan/China routine availability because direct regulator labels were not fetched; high for manufacturer-stated approvals and trial geography/status. No direct conflict identified. argenx — manufacturer regulatory approval announcement
  • efgartigimod / ARGX-113 / efgartigimod PH20 SC; rozanolixizumab (Rystiggo); zilucoplan (Zilbrysq); ravulizumab (Ultomiris); eculizumab (Soliris); nipocalimab; ALXN1720; iptacopan; pozelimab plus cemdisiran; cladribine; batoclimab; mycophenolate mofetil (CellCept)Clinical trial · NCT07247279Clinical trialTrial only (registry)Russia · anti-AChR antibody-positive in several trial titles/eligibility contexts; antibody scope varies by study; Adult and pediatric gMG treatment studies, extension studies, pregnancy safety registry, refractory/severe/exacerbation studies, and observational treatment-approach registry depending on NCT. · Registry participation does not establish routine national approval or reimbursement. Some studies are completed, active-not-recruiting, recruiting, terminated, unknown, or observational; each NCT must be checked before discussing current enrollment. Thailand remains source-pending for direct treatment/access. Confidence/conflicts: High for registry geography/status and Thailand no-hit sweep; low for routine Russia/Thailand access because direct regulator or payer sources were not verified. ClinicalTrials.gov — observational registry
  • efgartigimod / ARGX-113 / efgartigimod PH20 SC; rozanolixizumab (Rystiggo); zilucoplan (Zilbrysq); ravulizumab (Ultomiris); eculizumab (Soliris); nipocalimab; ALXN1720; iptacopan; pozelimab plus cemdisiran; cladribine; batoclimab; mycophenolate mofetil (CellCept)Clinical trial · NCT07247279Clinical trialTrial only (registry)Russia · anti-AChR antibody-positive in several trial titles/eligibility contexts; antibody scope varies by study; Adult and pediatric gMG treatment studies, extension studies, pregnancy safety registry, refractory/severe/exacerbation studies, and observational treatment-approach registry depending on NCT. · Registry participation does not establish routine national approval or reimbursement. Some studies are completed, active-not-recruiting, recruiting, terminated, unknown, or observational; each NCT must be checked before discussing current enrollment. Thailand remains source-pending for direct treatment/access. Confidence/conflicts: High for registry geography/status and Thailand no-hit sweep; low for routine Russia/Thailand access because direct regulator or payer sources were not verified. ClinicalTrials.gov — observational registry
  • efgartigimod / ARGX-113 / efgartigimod PH20 SC; rozanolixizumab (Rystiggo); zilucoplan (Zilbrysq); ravulizumab (Ultomiris); eculizumab (Soliris); nipocalimab; ALXN1720; iptacopan; pozelimab plus cemdisiran; cladribine; batoclimab; mycophenolate mofetil (CellCept)Clinical trial · NCT07247279Clinical trialTrial only (registry)Russia · anti-AChR antibody-positive in several trial titles/eligibility contexts; antibody scope varies by study; Adult and pediatric gMG treatment studies, extension studies, pregnancy safety registry, refractory/severe/exacerbation studies, and observational treatment-approach registry depending on NCT. · Registry participation does not establish routine national approval or reimbursement. Some studies are completed, active-not-recruiting, recruiting, terminated, unknown, or observational; each NCT must be checked before discussing current enrollment. Thailand remains source-pending for direct treatment/access. Confidence/conflicts: High for registry geography/status and Thailand no-hit sweep; low for routine Russia/Thailand access because direct regulator or payer sources were not verified. ClinicalTrials.gov — observational registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.